Widely-released "Internal" FDA report's post-market claim are flawed, says industry
This article was originally published in Clinica
US industry officials are challenging the results of the FDA's recent high-profile study, which found that a significant percentage of post-market studies are never completed, writes Karen Riley at the Food and Drug Law Institute annual meeting.
You may also be interested in...
Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.
Recommendations from the Alliance for Regenerative Medicine aim to improve cross-border healthcare to ensure patients can access advanced therapies.
At the OurCrowd Global Investor Summit in Jerusalem, Israel, on 13 February, Medtech Insight met wound care device company Nanomedic to find out more about its unique electro-spinning technology.